Document:

EX-10.1

 Exhibit 10.1 

CERTAIN MATERIAL (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 AMENDMENT TO
COLLABORATION AND LICENSE AGREEMENT 
 This AMENDMENT
TO THE COLLABORATION AND LICENSE AGREEMENT (the “Amendment”) is effective as of May 22, 2017 (the “Amendment
Effective Date”) by and between CHEMOCENTRYX, INC., a Delaware corporation, having an address at 850 Maude Avenue, Mountain View, CA 94043, U.S. (“ChemoCentryx”), and
VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD., a corporation organized under the laws of Switzerland, having an address at Rechenstrasse
37, CH-9014 St. Gallen, Switzerland (“VFMCRP”). ChemoCentryx and VFMCRP may be referred to herein individually as a “Party” or collectively as the “Parties”. 

RECITALS 

A. ChemoCentryx and VFMCRP are parties to that certain Collaboration and License Agreement, dated May 9, 2016 (the
“Agreement”), pursuant to which ChemoCentryx granted VFMCRP an exclusive license to commercialize ChemoCentryx’s proprietary C5aR inhibitor known as CCX168 in certain countries. The Agreement was originally entered into between
Vifor (International) Ltd. (“VIT”) and ChemoCentryx and was subsequently assigned by VIT to VFMCRP. 
 B. On
February 8, 2017, ChemoCentryx and Vifor (International) Ltd. (“Vifor”) entered into a letter agreement pursuant to which ChemoCentryx granted Vifor an exclusive license to commercialize CCX168 in all countries of the world
(excluding the U.S. and China) that were not previously licensed to VFMCRP, and Vifor paid ChemoCentryx ten million United States dollars (US$10,000,000), equal to one-half of the total upfront payment for such rights. Such letter agreement is
terminated concurrently with the Parties’ entry into this Amendment. 
 C. This Amendment, which includes an option to expand
the territory licensed to VFMCRP to include China, and which is being entered into in accordance with Section 16.2 of the Agreement, provides for such territory expansion and payment therefor by VFMCRP in accordance with the terms and
conditions of this Amendment. 
 NOW, THEREFORE, the Parties agree as follows: 

 

	1.	AMENDMENT OF THE AGREEMENT 

The Parties hereby agree to amend the terms of the Agreement as provided below, effective as of the Amendment Effective Date. Except to the
extent the Agreement is explicitly amended by this Amendment, the Agreement will remain in full force and effect in accordance with its terms. Capitalized terms used in this Amendment that are not otherwise defined herein shall have the meanings
such terms are given in the Agreement. 
 1.1 All references in the Agreement to “VIT” are hereby amended to refer instead
to “VFMCRP”. 

  

					
		 		  	Confidential

 1.2 Section 1.85 of the Agreement is hereby deleted and replaced in its entirety with
the following: 
 1.85 “Major Market Countries” means France, Switzerland, Germany, Italy, Spain, the United Kingdom,
Brazil, Japan, Canada, Mexico, South Korea and, if added to the VFMCRP Territory pursuant to Section 2.11, China. 
 1.3
Section 1.134 of the Agreement is hereby deleted and replaced in its entirety with the following: 
 1.134 “VFMCRP
Territory” means (a) the world, excluding the U.S. and China, and (b) China, if China is added to the VFMCRP Territory pursuant to Section 2.11. 

1.4 The following new definitions are hereby added to the end of Article 1 of the Agreement as new Sections 1.136, 1.137 and 1.138:

 1.136 “China” means the People’s Republic of China, the Hong Kong Special Administrative Region of the
People’s Republic of China and the Macao Special Administrative Region of the People’s Republic of China. 
 1.137
“China Agreement” has the meaning set forth in Section 2.11. 
 1.138 “China Agreement
Revenue” means all amounts received by ChemoCentryx from a Third Party under a China Agreement, but specifically excluding: (a) amounts received in consideration of the issuance of equity or debt securities of ChemoCentryx or its
Affiliate; (b) payments for research, development, or commercialization activities undertaken by ChemoCentryx or its Affiliate; (c) reimbursements for amounts paid or costs incurred by or on behalf of ChemoCentryx or its Affiliate,
including patent prosecution, maintenance, enforcement or defense expenses; (d) amounts received as an extension of credit or loan or as a distribution of a patent enforcement award; or (e) payments for the supply of goods and/or services.
Notwithstanding the foregoing, if an upfront payment under a China Agreement includes amounts received in consideration of the issuance of equity or debt securities of ChemoCentryx or its Affiliate, [***] will be included in China Agreement Revenue.
[***]. In the event that ChemoCentryx grants rights to the Product along with a license to any proprietary technology or intellectual property related to products other than the Product, ChemoCentryx shall reasonably and in good faith allocate the
amounts received among all technology licensed or sublicensed, and China Agreement Revenue shall include only the portion allocated to the Product. For clarity, China Agreement Revenue excludes amounts received by ChemoCentryx from a Third Party in
connection with a sale of substantially all of the business or assets to which this Agreement relates. 
 1.5 The last sentence of
Section 2.10(d) of the Agreement and Section 2.10(e) of the Agreement are hereby deleted. 
  

 

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

  

					
		 	2	  	Confidential

 1.6 The following new Section 2.11 is hereby added to the Agreement: 

2.11 China. ChemoCentryx shall notify VFMCRP within thirty (30) days after entering into a written agreement with a Third Party
for development of the Product for Regulatory Approval in China (a “China Agreement”). If ChemoCentryx has not entered into a China Agreement by [***], then VFMCRP may elect to expand the VFMCRP Territory to include China by
(a) delivering written notice of such expansion to ChemoCentryx and (b) paying ChemoCentryx a one-time, non-refundable, non-creditable payment of [***] United States dollars (US$[***]), in each case (a) and (b) within thirty
(30) days after [***]. Upon ChemoCentryx’s receipt of such notice and payment during such thirty (30)-day period, the VFMCRP Territory will automatically be expanded to include China. If ChemoCentryx does not receive such notice and
payment during such thirty (30)-day period, the VFMCRP Territory shall continue to exclude China. 
 1.7 The following new
Section 8.5 is hereby added to the Agreement: 
 8.5 China Agreement Revenue. Within sixty (60) days after the end of each
Calendar Quarter in which ChemoCentryx receives China Agreement Revenue, ChemoCentryx shall pay to VFMCRP an amount equal to [***] percent ([***]%) of all China Agreement Revenue received by ChemoCentryx during such Calendar Quarter. 

1.8 Section 9.4 of the Agreement is hereby deleted and replaced in its entirety with the following: 

9.4 Records; Audit. VFMCRP shall keep, and shall cause its Affiliates and Sublicensees to keep, complete and accurate records
pertaining to the sale or other disposition of the Product in sufficient detail to permit ChemoCentryx to confirm the accuracy of commercial milestone and royalty payments due hereunder. ChemoCentryx shall keep, and shall cause its Affiliates to
keep, complete and accurate records pertaining to the China Agreement Revenue received by ChemoCentryx in sufficient detail to permit VFMCRP to confirm the accuracy of payments due under Section 8.5. Such records shall be kept for such period
of time required by Applicable Laws, but in no case less than three (3) years following the end of the Calendar Quarter to which they pertain. Each Party shall have the right to have an independent, certified public accountant reasonably
acceptable to the other Party audit such records of the other Party to confirm Net Sales, royalties, and other payments, in the case of VFMCRP as audited Party, and to confirm China Agreement Revenue, in the case of ChemoCentryx as audited Party,
for a period covering not more than three (3) years following the Calendar Quarter to which they pertain. Such audits may be exercised only once for any period and no more than once per Calendar Year during normal business hours upon reasonable
prior written notice to the audited Party. Any such auditor shall not disclose the audited Party’s confidential information to the auditing 
  

 

	***	 Certain information on this page has been omitted and filed separately with the Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  

					
		 	3	  	Confidential

 
Party, except to the extent such disclosure is necessary to verify the accuracy of the financial reports furnished by the audited Party or the amount of payments by the audited Party under this
Agreement. Any amounts shown to be owed but unpaid shall be paid within thirty (30) days after the accountant’s report, plus interest (as set forth in Section 9.5) from the original due date. Any overpayment by the audited Party
revealed by an audit shall be credited against future payments owed by the audited Party to the other Party (and if no further payments are due, shall be refunded by the auditing Party at the request of the audited Party). The auditing Party shall
bear the full cost of such audit unless such audit discloses an underpayment by the audited Party of more than five percent (5%) of the amount of royalties or other payments due under this Agreement for any applicable Calendar Quarter, in which
case, the audited Party shall bear the cost of such audit. 
  

	2.	PAYMENTS 

 2.1 In consideration for the expansion of the VFMCRP
Territory as set forth in this Amendment, VFMCRP shall make a non-refundable, non-creditable payment to ChemoCentryx of ten million United States dollars (US$10,000,000) on or before February 8, 2018;
provided that if the Agreement is terminated prior to such date, such payment shall remain due and payable despite such termination, unless the Agreement is terminated by VFMCRP pursuant to Section 14.3 of the Agreement. 

 

	3.	MISCELLANEOUS 

 3.1 Full Force and Effect. This Amendment amends
the terms of the Agreement and is deemed incorporated into the Agreement. The provisions of the Agreement, as amended by this Amendment, remain in full force and effect. 

3.2 Entire Agreement. The Agreement, as amended by this Amendment constitute the entire agreement, both written and oral, between the
Parties with respect to the subject matter hereof, and any and all prior agreements with respect to the subject matter hereof, either written or oral, expressed or implied, are superseded hereby, merged and canceled, and are null and void and of no
effect. 
 3.3 Counterparts. This Amendment may be executed in one or more counterparts, each of which will be an original and all of
which together will constitute one instrument. 

  

					
		 	4	  	Confidential

 IN WITNESS WHEREOF, the
Parties have executed this Amendment as of the Amendment Effective Date. 
  

									
	CHEMOCENTRYX, INC.	 		 	VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD.
					
	By:	 	         /s/ Thomas J. Schall, Ph.D.	 		 	By:	 	         /s/ Stefan Schulze

									
					
	Name:	 	         Thomas J. Schall, Ph.D.	 		 	Name:	 	          Stefan Schulze
					
	Title:	 	         Chief Executive Officer	 		 	Title:	 	          CEO

 

									
					
		 		 		 	By:	 	         /s/ Chris Springer

									
				
		 		 	Name:	 	          Chris Springer
				
		 		 	Title:	 	          Deputy CEO

  

					
		 		  	ConfidentialEX-10.2

 Exhibit 10.2 

SECOND AMENDMENT TO LEASE 

THIS SECOND AMENDMENT TO LEASE (this “Amendment”) is made and entered into effective as of April 13,
2017 (the “Effective Date”), by and between GOOGLE INC., a Delaware corporation (“Landlord” or “Lessor”), and CHEMOCENTRYX, INC., a Delaware corporation (“Tenant” or
“Lessee”). 

R E C I T A L S : 

A.        Landlord and Tenant are parties to that certain Lease (as defined below),
pursuant to which Landlord is currently leasing to Tenant, and Tenant is currently leasing from Landlord, certain space (the “Premises”) containing approximately 35,755 rentable square feet and located in that certain building
addressed as 840-850 Maude Avenue, Mountain View, California (the 
 “Building”). As used herein,
“Lease” shall mean and refer, collectively, to the following document(s): 
  

	 	i.	 Standard Industrial/Commercial Multi-Tenant Lease – Net dated as of April 20, 2004 (the “Original
Lease”), between Portola Land Company, a California limited partnership (“Portola”) (as predecessor-in-interest to Landlord), and Tenant
(incorrectly referred to as “ChemoCentryx Inc., a Delaware corporation”); and 

  

	 	ii.	 First Amendment to Lease Agreement dated as of August 16, 2012 (the “First Amendment”),
between Portola (as predecessor-in-interest to Landlord), and Tenant (incorrectly referred to as “ChemoCentryx,. a Delaware corporation”).

  

B.        Landlord and Tenant now desire to amend the Lease (i) to further extend
the term of the Lease, and (ii) to modify various terms and provisions of the Lease, all as hereinafter provided. 

A G R E E M E N T : 

NOW THEREFORE, in consideration of the foregoing recitals and the mutual covenants contained herein, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

1.        Capitalized Terms.  All capitalized terms when used herein
shall have the same meanings given such terms in the Lease unless expressly superseded by the terms of this Amendment. 

2.        Extension of Lease Term.  The term of the Lease, as
previously extended by Section 2 of the First Amendment, which is currently scheduled to expire on April 30, 2019, is hereby extended for a period of one (1) year (the “Second Extended Term”), commencing on May 1,
2019 (the “Second Extended Term Commencement Date”) and expiring on April 30, 2020, unless sooner terminated pursuant to the terms of the Lease, as hereby amended. 

  
 -1- 

 3.         Rent.  Prior
to the Second Extended Term, the Base Rent payable by Tenant shall continue to be as set forth in the Lease. During the Second Extended Term, Tenant shall pay monthly installments of Base Rent to Landlord for the Premises as set forth in the
following schedule: 
  

					
	 Period of Second

Extended Term
	  	 Annual

Base Rent
	  	 Monthly Installment

of Base Rent

			
	5/1/2019 - 4/30/2020	  	$1,501,710.00	  	$125,142.50

 Tenant shall continue to pay Lessee’s Share of Common Area Operating Expenses (including,
without limitation, Real Property Taxes) in accordance with the terms of the Lease. 

4.        Condition of Premises.  Tenant is currently in possession
of the Premises and shall continue to accept and occupy the Premises and the Building in their current “AS IS” condition as of the Effective Date and the Second Extended Term Commencement Date without any agreements, representations,
understandings or obligations on the part of Landlord to perform or pay for any alterations, repairs or improvements to the Premises, except as otherwise expressly set forth in the Lease, as hereby amended. 

5.        Landlord’s Address for Notices.  Effective as of the
Effective Date, all notices, consents, demands and other communications delivered by Tenant to Landlord pursuant to and in accordance with the Lease must be addressed to the following addresses: 

Originals sent to: 
 Google
Inc. 
 1600 Amphitheatre Parkway 

Mountain View, California 94043 

Attention: Lease Administration 

and 
 Google Inc. 

1600 Amphitheatre Parkway 

Mountain View, California 94043 

Attention: Legal Department / RE Matters 

With a copy sent to: 
 Google
Inc. 
 c/o Orchard Commercial, Inc. 

2055 Laurelwood Road, Suite 130 

Santa Clara, California 95054 

Attention: Shannon Freitag. 

  
 -2- 

 6.        California Statutory CASp
Disclosure.  For purposes of Section 1938(a) of the California Civil Code, Landlord hereby discloses to Tenant, and Tenant hereby acknowledges, that the Premises have not undergone inspection by a Certified Access Specialist
(CASp). In addition, the following notice is hereby provided pursuant to Section 1938(e) of the California Civil Code: “A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply
with all of the applicable construction-related accessibility standards under state law. Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant
from obtaining a CASp inspection of the subject premises for the occupancy or potential occupancy of the lessee or tenant, if requested by the lessee or tenant. The parties shall mutually agree on the arrangements for the time and manner of the CASp
inspection, the payment of the fee for the CASp inspection, and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the premises.” In furtherance of and in connection with such
notice: (i) Tenant, having read such notice and understanding Tenant’s right to request and obtain a CASp inspection and with advice of counsel, hereby elects not to obtain such CASp inspection and forever waives its rights to obtain a CASp
inspection with respect to the Premises, the Building, and/or the Project to the extent permitted by applicable laws now or hereafter in effect; and (ii) if the waiver set forth in clause (i) hereinabove is not enforceable pursuant to
applicable laws now or hereafter in effect, then Landlord and Tenant hereby agree as follows (which constitute the mutual agreement of the parties as to the matters described in the last sentence of the foregoing notice): (A) Tenant shall have the one-time right to request for and obtain a CASp inspection, which request must be made, if at all, in a written notice delivered by Tenant to Landlord on or before the Second Extended Term Commencement Date;
(B) any CASp inspection timely requested by Tenant shall be conducted (1) between the hours of 9:00 a.m. and 5:00 p.m. on any business day, (2) only after ten (10) days’ prior written notice to Landlord of the date of such
CASp inspection, (3) in a professional manner by a CASp designated by Landlord and without any testing that would damage the Premises, the Building, or the Project in any way, (4) in accordance with all of the provisions of the Lease
applicable to Tenant contracts for construction, and (5) at Tenant’s sole cost and expense, including, without limitation, Tenant’s payment of the fee for such CASp inspection, the fee for any reports and/or certificates prepared by
the CASp in connection with such CASp inspection (collectively, the “CASp Reports”) and all other costs and expenses in connection therewith; (C) Landlord shall be an express third party beneficiary of Tenant’s contract
with the CASp, and any CASp Reports shall be addressed to both Landlord and Tenant; (D) Tenant shall deliver a copy of any CASp Reports to Landlord within two (2) business days after Tenant’s receipt thereof; (E) any information
generated by the CASp inspection and/or contained in the CASp Reports shall not be disclosed by Tenant to anyone other than (I) contractors, subcontractors and/or consultants of Tenant, in each instance who have a need to know such information
and who agree in writing not to further disclose such information, or (II) any governmental entity, agency or other person, in each instance to whom disclosure is required by law or by regulatory or judicial process; (F) Tenant, at its
sole cost and expense, shall be responsible for making any improvements, alterations, modifications and/or repairs to or within the Premises to correct violations of construction-related accessibility standards, including, without limitation, any
violations disclosed by such CASp inspection; and (G) if such CASp inspection identifies any improvements, alterations, modifications and/or repairs necessary to correct violations of construction-related accessibility standards relating to
those items of the Building and/or the 

  
 -3- 

 
Project located outside the Premises that are Landlord’s obligation to repair as set forth in the Lease, then Landlord shall perform such improvements, alterations, modifications and/or
repairs as and to the extent required by applicable laws to correct such violations, and Tenant shall reimburse Landlord for the cost of such improvements, alterations, modifications and/or repairs within ten (10) business days after
Tenant’s receipt of an invoice therefor from Landlord. 
 7.        
Brokers.  Landlord and Tenant each hereby represents and warrants to the other that it has had no dealings with any real estate broker or agent in connection with the negotiation of this Amendment, except for Orchard Commercial,
representing Landlord (the “Broker”), and that it knows of no other real estate broker or agent who is entitled to a commission in connection with this Amendment. Each party agrees to indemnify and defend the other
party against and hold the other party harmless from any and all claims, demands, losses, liabilities, lawsuits, judgments, and costs and expenses (including, without limitation, reasonable attorneys’ fees) with respect to any leasing
commission or equivalent compensation alleged to be owing on account of any breach of the foregoing representation and warranty by the indemnifying party in connection with this Amendment. 

8.        Authority.  If Tenant is a corporation, trust, limited
liability company or partnership, each individual executing this Amendment on behalf of Tenant hereby represents and warrants that Tenant is a duly formed and existing entity qualified to do business in California and that Tenant has full right and
authority to execute and deliver this Amendment and that each person signing on behalf of Tenant is authorized to do so. In such event, Tenant shall, within ten (10) days after Landlord’s written request, deliver to Landlord satisfactory
evidence of such authority, and, upon demand by Landlord, Tenant shall also deliver to Landlord satisfactory evidence of: (i) good standing in Tenant’s state of formation; and (ii) qualification to do business in California. 

9.        Counterparts.  This Amendment may be executed in any number
of counterparts, which may be delivered electronically, via facsimile or by other means. Each party may rely upon signatures delivered electronically or via facsimile as if such signatures were originals. Each counterpart of this Amendment shall be
deemed to be an original, and all such counterparts (including those delivered electronically or via facsimile), when taken together, shall be deemed to constitute one and the same instrument. 

10.        No Options; No Allowances.  Notwithstanding anything to
the contrary contained in the Lease, as hereby amended, Tenant hereby acknowledges and agrees that except as otherwise expressly set forth above in this Amendment: (i) Tenant has no (A) options to extend or renew the Lease, (B) early
termination options, (C) options or rights to expand the Premises or to lease additional space in the real property of which the Premises are a part, (D) rights of first offer and/or rights of first refusal to lease any space in the real
property of which the Premises are a part, and (E) options or preferential rights to purchase all or any portion of the Premises or the real property of which the Premises are a part nor any other rights or interests with respect to the Premises or
the real property of which the Premises are a part, other than as “Tenant” under the Lease; and (ii) Tenant is not entitled to any improvement allowance, free or abated rent or any other concessions under the Lease; including, without
limitation, the HVAC Upgrade Allowance (as defined in Section 5.1 of the First Amendment). 

  
 -4- 

 11.        No Further
Modification.  Except as set forth in this Amendment, all of the terms and provisions of the Lease are hereby ratified and confirmed and shall remain unmodified and in full force and effect. In the event of any conflict between the
terms and conditions of the Lease and the terms and conditions of this Amendment, the terms and conditions of this Amendment shall prevail. 

[SIGNATURES CONTAINED ON THE FOLLOWING PAGE] 

  
 -5- 

 IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed by their duly
authorized representatives as of the date first above written. 
  

									
	“LANDLORD”:	 		 	“TENANT”:
			
	GOOGLE INC.,	 		 	CHEMOCENTRYX, INC.,
	a Delaware corporation	 		 	a Delaware corporation
					
	By:	 	        /s/ David Radcliffe	 		 	By:	 	        /s/ Markus J. Cappel

									
					
	Name:	 	        David Radcliffe	 		 	Name:	 	        Markus J. Cappel

									
					
	Title:	 	          VP. Real Estate	 		 	Title:	 	          Chief Business Officer

 

									
					
		 		 		 	By:	 	 

									
					
	 

	 		 		 	Name:	 	 
	 		 		 	Title:	 	 

  
 -6-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}]]